查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1690113

藥用管瓶和安瓿瓶：市場佔有率分析、產業趨勢和成長預測（2025-2030 年）

Pharmaceutical Glass Vials And Ampoules - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
出版日期: | 出版商: Mordor Intelligence | 英文 154 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計 2025 年藥用管瓶和安瓿瓶市場規模為 158.5 億美元，到 2030 年將達到 221.7 億美元，預測期內（2025-2030 年）的複合年成長率為 6.94%。

藥用玻璃瓶和安瓿瓶-市場-IMG1

玻璃長期以來一直是醫藥包裝行業安全包裝的黃金標準，是保持各種化學成分的完美材料。此外，玻璃管瓶和安瓿瓶透明度高，易於檢查和監控其內容物。

主要亮點

  • 製藥業的成長推動著市場的成長。人口稠密的國家對藥用管瓶和安瓿瓶的需求較大。這些國家正在增加藥品產量，進一步增加了需求。此外，印度和中國等新興經濟體醫療保健支出的增加也推動了市場成長。
  • 新興市場因其良好的人口結構、低廉的人事費用和豐富的資源而被認為是一個不斷成長和繁榮的國家。金磚國家（巴西、俄羅斯、印度、中國和南非）是領先的新興經濟體。
  • 對子經濟體進行分類有幾種不同的方法。 MIST 國家包括墨西哥、印尼、韓國和土耳其。還有一種解釋是把這些國家分為靈貓國（哥倫比亞、印尼、越南、埃及、土耳其和南非）和孟加拉、埃及、印尼、伊朗、韓國、墨西哥、奈及利亞、巴基斯坦、菲律賓、土耳其和越南。
  • 玻璃的關鍵性能優勢，例如其化學耐久性和保持多種化學成分的能力，正在促使包裝供應商選擇它作為醫藥材料。
  • 此外，玻璃管瓶和安瓿瓶透明度高，可輕鬆檢視和監控內容物。由於玻璃對大多數藥物具有耐化學性，並且相對滲透性空氣和水分，因此這提供了進一步的保護。
  • 傳統上，藥品包裝所使用的材料是鋁和玻璃。隨著時間的推移，這些材料由於原料價格和其他因素而變得昂貴，並且不再為包裝大眾消費產品提供經濟可行的解決方案。這時，塑膠就成為一種選擇。

藥用管瓶和安瓿瓶的市場趨勢

疫苗將佔據很大市場佔有率

  • 疫苗需求的增加以及慢性病盛行率的上升推動了醫藥包裝產業的整體成長。因此，管瓶和安瓿瓶市場預計將大幅成長。
  • 疫苗包裝解決方案需求的激增得益於消費者購買的大量疫苗以及世界衛生組織和聯合國兒童基金會等主流組織組織的大規模疫苗接種活動。這導致醫院、診斷中心、研究項目和其他醫療保健單位等終端使用領域對玻璃安瓿瓶和管瓶的需求大幅增加。
  • 此外，由於持續控制感染疾病的努力、大流行病的爆發以及對疫苗接種重要性的認知不斷提高等各種因素，全球對疫苗的需求正在穩步成長。
  • 在整個製造過程中，技術轉移和夥伴關係將顯著影響供應的靈活性和擴充性，尤其是在 COVID-19 疫苗的開發過程中。許多製造商從其他製造商接收散裝疫苗，然後將其裝入管瓶、安瓿瓶和包裝中進行分發。
  • 藥品包裝（尤其是疫苗包裝）的嚴格監管要求通常傾向於使用玻璃，因為玻璃具有化學惰性且能夠承受滅菌過程。這種合規性推動了對藥品包裝中管瓶和安瓿瓶的需求。確保為全球疫苗分發提供足夠的藥用管瓶供應對於全球應對的成功至關重要。世界各國政府和製藥公司正在下達數億份訂單，促使初級包裝玻璃製造商提高生產能力。
  • 這些努力在許多國家都取得了成功，各國政府都採購並管理了疫苗。例如，截至 2023 年 11 月，印度政府已接種超過 22 億劑 COVID-19 疫苗。根據CNN和OWID報道，截至2023年3月20日，全球已接種約130億劑新冠疫苗，其中美國接種了約6.72億劑。

亞太地區：預計大幅成長

  • 隨著中國建立了製藥業的標準框架，中國藥用玻璃安瓿瓶和管瓶市場預計將擴大。在國內，人們越來越重視藥品包裝材料在藥品儲存過程中的穩定性以及包裝在使用時的安全性。由於玻璃包裝具有耐用性、非反應性、透明度、環境相容性和多功能性，製藥公司擴大採用玻璃包裝。此外，由於醫療保健系統和研發方面的投資增加以及醫藥支出的增加，管瓶的需求量很大。
  • 日本製藥業是繼美國之後世界上成長最快的產業之一。這是因為日本持續致力於開發學名藥及疫苗，以及政府對希望在日本投資的國際公司採取放鬆管制的措施。 2023年5月，全球最大的公司之一日本尼普洛株式會社（Nipro Corporation Japan）宣布將在塞斯韋特（Sesvete）工廠投資超過1億披索（2648萬美元），為製藥業建造一個新的安瓿瓶和管瓶工廠（藥品），即尼普洛製藥（克羅埃西亞）。 Nipro Corporation Japan 從 Blue Sea Capital Fund 手中收購了前 Piramida 工廠（Sesvete）（最近被評為年度最成功的收購）。
  • 隨著印度製藥業的成長，印度對玻璃包裝的需求預計將會增加。隨著行業參與者專注於抓住市場成長，他們正在建立玻璃管設施，以幫助製藥商應對日益複雜的產能和品質挑戰，同時滿足印度市場對基本藥物的需求。
  • 例如，2023年7月，美國科技公司康寧與法國藥用玻璃製造商SGD Pharma的合資企業將在印度特倫甘納邦建立一家藥用玻璃管工廠，以擴大印度的藥品生產規模。新廠將康寧專有的玻璃塗層技術平台 Velocity 管瓶與 SGD Pharma 的管瓶轉換專業知識相結合，以提高管瓶和填充生產線的生產效率，並加速全球注射療法的交付。
  • 新工廠的奠基儀式將於 2023 年 6 月舉行，該公司預計將向該工廠投資約 50 億印度盧比（6,030 萬美元），並創造約 150 個就業機會。 Velocity管瓶的生產預計將於 2024 年在 SGD Pharma 的 Vemula 工廠開始，藥用導管的生產預計將於 2025 年開始。
  • 注射劑的需求正在成長，因為它們避免了口服營養素所帶來的許多問題。隨著醫療保健需求的增加，對管瓶和安瓿瓶包裝的藥品、疫苗和其他醫療產品的需求也在增加，這給這些藥品的生產帶來了壓力。這導致製藥公司轉向契約製造。例如，2023年5月，創新軟體、生命科學和深度科技公司開發商Bridgewest Group推出了一家專注於無菌注射藥物的新的合約開發和受託製造廠商（CDMO）。 CMDO 將設在西澳大利亞，並在 NovaCina 旗下運作。

藥用管瓶和安瓿瓶產業概況

藥用管瓶和安瓿瓶市場分散，主要參與者包括 Schott AG、Gerresheimer AG、Stevanato Group、Nipro Corporation 和 Kapoor Glass India Pvt。有限公司。市場上的公司正在採取聯盟和收購等策略來加強其產品供應並獲得永續的競爭優勢。

  • 2023 年 10 月 - Gerresheimer 推出 COP（環狀烯烴聚合物）管瓶，這是適用於填充和儲存敏感生物製藥的解決方案。 COP管瓶非常適合在低溫和低溫環境中與 mRNA 活性成分一起使用。 Gerresheimer 提供各種品質的 RTF管瓶，採用結合了玻璃和塑膠最佳性能的高品質聚合物。
  • 2023 年 2 月 - NOVA Ompi 簽署預售協議，以約 1.6 億歐元（1691 萬美元）的價格收購位於義大利拉廷的一塊棕地地，該地靠近斯蒂瓦那托集團的其他工廠。維修後，棕地工廠將生產 EZ-fill 注射器、管瓶和其他產品。

其他福利

  • Excel 格式的市場預測 (ME) 表
  • 3個月的分析師支持

目錄

第1章 引言

  • 研究假設和市場定義
  • 研究範圍

第2章調查方法

第3章執行摘要

第4章 市場洞察

  • 市場概覽
  • 產業吸引力－波特五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭對手之間的競爭強度
  • COVID-19 產業影響評估
  • 產業價值鏈分析

第5章市場動態

  • 市場促進因素
    • 新興國家製藥業的成長
    • 提高可回收玻璃的商業價值
  • 市場限制
    • 替代原料的重要性日益增加

第6章市場區隔

  • 按應用
    • 疫苗
    • 其他（胰島素、生物製藥等）
  • 按地區
    • 北美洲
      • 美國
      • 加拿大
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
    • 亞洲
      • 中國
      • 日本
      • 印度
      • 韓國
      • 澳洲和紐西蘭
    • 拉丁美洲
    • 中東和非洲

第7章競爭格局

  • 公司簡介
    • Schott AG
    • Gerresheimer AG
    • Stevanato Group SPA
    • NIPRO Corporation
    • Kapoor Glass India Pvt. Ltd
    • SGD SA（SGD Pharma）
    • AAPL Solutions Pvt. Ltd
    • CORNING INCORPORATED
    • BOROSIL
    • Stoelzle Oberglas GmbH
    • Accu-Glass LLC
    • Adit Containers Private Limited
    • Agrado SA
    • Birgimefar Group
    • J. Penner Corporation
    • BORMIOLI PHARMA SPA
    • SISECAM

第8章投資分析

第9章：市場的未來

簡介目錄
Product Code: 69988

The Pharmaceutical Glass Vials And Ampoules Market size is estimated at USD 15.85 billion in 2025, and is expected to reach USD 22.17 billion by 2030, at a CAGR of 6.94% during the forecast period (2025-2030).

Pharmaceutical Glass Vials And Ampoules - Market - IMG1

Glass has long been the go-to material for safe packaging in the pharmaceutical packaging industry and is best suited to sustaining various chemical compositions. Also, glass vials and ampoules provide enhanced transparency, which allows easy inspection and monitoring of their contents.

Key Highlights

  • The growing pharmaceutical industry aids the market's growth. The demand for pharmaceutical glass vials and ampoules arises in densely populated countries. The increasing pharmaceutical production in these countries is further increasing demand. In addition, growing healthcare spending in developing countries like India and China is another driver of the market's growth.
  • Emerging markets are described as growing and prosperous nations owing to their favorable demographic conditions, low labor costs, and abundant resources. The BRICS nations (Brazil, Russia, India, China, and South Africa) are the top developing economies.
  • There are a few different approaches to classifying lower-tier economies. MIST countries include Mexico, Indonesia, South Korea, and Turkey. Another interpretation separates the two groups into CIVETS (Colombia, Indonesia, Vietnam, Egypt, Turkey, and South Africa) and Bangladesh, Egypt, Indonesia, Iran, Korea, Mexico, Nigeria, Pakistan, the Philippines, Turkey, and Vietnam.
  • The significant characteristic benefits of glass, such as chemical durability and suitability to sustain various chemical compositions, are some factors driving packaging vendors to choose glass as a pharmaceutical material.
  • Additionally, glass vials and ampoules offer improved transparency, making viewing and monitoring the contents easier. This provides additional protection because glass is chemically resistant to most pharmaceuticals and comparatively impermeable to air and moisture.
  • Traditionally, the preferred materials across pharmaceutical packaging have been aluminum and glass. Over time, these materials became expensive due to raw material prices and other factors and could not provide economically viable solutions for packaging products across mass consumption. That marked the advent of plastics as an option.

Pharmaceutical Glass Vials and Ampoules Market Trends

Vaccines to Hold Significant Market Share

  • The increasing demand for vaccines, coupled with the rising prevalence of chronic diseases, contributes to the overall growth of the pharmaceutical packaging industry. The market for glass vials and ampoules is expected to witness a substantial increase as a result.
  • The surge in demand for vaccine packaging solutions is aided by the high number of vaccines acquired by consumers and the major vaccination drives organized by mainstream organizations like WHO and UNICEF. This has led to a significant increase in demand for glass ampoules and vials in end-use sectors such as hospitals, diagnostic centers, research programs, and other healthcare units.
  • Furthermore, the global demand for vaccines has been steadily increasing due to various factors, including ongoing efforts to combat infectious diseases, emerging pandemics, and a growing awareness of the importance of vaccination.
  • The flexibility and scalability of supply are greatly impacted by technology transfers and partnerships throughout the manufacturing process, particularly with the development of COVID-19 vaccines. Many manufacturers rely on receiving bulk vaccines from another manufacturer that they then fill into vials, ampoules, and packages for distribution.
  • Stringent regulatory requirements for pharmaceutical packaging, especially for vaccines, often favor using glass due to its chemical inertness and the ability to withstand sterilization processes. This compliance drives the demand for glass vials and ampoules in pharmaceutical packaging. Ensuring an adequate supply of pharmaceutical glass vials for the distribution of the vaccine worldwide is crucial for the success of a global response. Governments and pharmaceutical companies worldwide are placing hundreds of millions of orders and urging primary packaging glass manufacturers to increase their production capacity.
  • These initiatives proved successful in many countries, acquiring and administrating vaccines by their respective governments. For example, as of November 2023, the Indian government had administered more than 2.2 billion COVID-19 vaccinations. According to CNN and OWID, as of March 20, 2023, about 13 billion COVID-19 vaccine doses had been administered globally, with the United States accounting for almost 672 million.

Asia Pacific Expected to Witness Major Growth

  • The Chinese pharmaceutical glass ampoules and vials market is expected to expand as China has established a standard framework for the pharmaceutical industry. The country is increasingly focusing on the stability of pharmaceutical packaging materials during drug storage and the safety of the packaging when used. Pharmaceutical companies increasingly use glass packaging because of its durability, non-reactivity, transparency, eco-friendliness, and versatility. Additionally, glass vials are in high demand due to increasing investment and R&D in healthcare systems and rising drug spending.
  • Japan's pharmaceutical industry is one of the fastest growing in the world, second only to the United States. This is due to the country's continued focus on developing generic and patented drugs and vaccines and the government's deregulatory measures for international companies wishing to invest in the country. In May 2023, Nipro Corporation Japan, one of the world's largest companies, presented its investment of over PGK 100 million (USD 26.48 million) at the Sesvete plant, where it is constructing a new ampoules and vial factory (Pharmaceuticals) Nippro Pharma Packaging (Hrvatska) for the pharmaceutical industry. Nippro Corporation Japan purchased the old Piramida factory (Sesvete) from the Blue Sea Capital fund (which was recently named the year's most successful acquisition).
  • The demand for glass packaging in India is expected to increase as the Indian pharmaceutical industry grows. Players in the industry are focusing on capitalizing on market growth, so they are opening glass tubing facilities to help the companies support drug manufacturers in addressing progressively complex capacity and quality challenges while fulfilling the need for essential medicines in the Indian market.
  • For instance, in July 2023, a joint venture between United States technology company Corning and French pharmaceutical glassmaker SGD Pharma will build a pharmaceutical glass tubing facility in the Indian state of Telangana to scale up pharmaceutical manufacturing in India. The new facility will bring together Corning's proprietary glass coating technology platform, Velocity Vial, and SGD Pharma's vial converting expertise to enhance vial and fill-line productivity and the delivery speed for injectable treatments worldwide.
  • The groundbreaking ceremony for the new facility was held in June 2023, and the company expects to invest approximately INR 5 billion (USD 60.3 million) in the facility, which is expected to create about 150 jobs. The manufacturing of Velocity Vials is expected to start at SGD Pharma's Vemula facility in 2024, with the production of pharmaceutical tubing expected to begin in 2025.
  • The demand for injectables is increasing as they can bypass many issues plaguing orally administered nutrients. As healthcare needs increase, the demand for pharmaceuticals, vaccines, and other medical products packaged in vials and ampoules will also increase, creating pressure on the production of such medicines. This leads to pharmaceutical companies switching to contract manufacturers. For instance, in May 2023, Bridgewest Group, a company developing innovative software, life sciences, and deep tech companies, launched a new contract development and manufacturing organization (CDMO) focusing on sterile injectable drug products. The CMDO is located in Western Australia and will operate under NovaCina.

Pharmaceutical Glass Vials and Ampoules Industry Overview

The pharmaceutical glass vials and ampoules market is fragmented, with the presence of major players like Schott AG, Gerresheimer AG, Stevanato Group, Nipro Corporation, and Kapoor Glass India Pvt. Ltd. Players in the market are adopting strategies such as partnerships and acquisitions to enhance their product offerings and gain sustainable competitive advantage.

  • October 2023 - Gerresheimer has launched vials containing COP (Cyclic Olefin Polymer), a suitable solution for filling and storing susceptible biological products. COP vials are ideal for using mRNA-active ingredients in cold and cryogenic environments. Gerresheimer is broadening its range of RTF glass vials, which are available in various qualities, with a high-quality polymer that combines the best properties of both glass and plastic.
  • February 2023 - NOVA Ompi entered into a pre-sale agreement to purchase a brownfield site in Latin (Italy), close to other facilities of the Stevanato group, for an approximate price of EUR 16,0 million (USD 16.91 million). After renovation, the brownfield site is expected to produce EZ-filled syringes, vials, and other products.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHTS

  • 4.1 Market Overview
  • 4.2 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.2.1 Bargaining Power of Suppliers
    • 4.2.2 Bargaining Power of Buyers
    • 4.2.3 Threat of New Entrants
    • 4.2.4 Threat of Substitutes
    • 4.2.5 Intensity of Competitive Rivalry
  • 4.3 Assessment of the Impact of COVID-19 on the Industry
  • 4.4 Industry Value Chain Analysis

5 MARKET DYNAMICS

  • 5.1 Market Drivers
    • 5.1.1 Growth of the Pharmaceutical Industry in Emerging Economies
    • 5.1.2 Commodity Value of Glass Increased with Recyclability
  • 5.2 Market Restraints
    • 5.2.1 Increased Relevance of Alternate Sources

6 MARKET SEGMENTATION

  • 6.1 By Application
    • 6.1.1 Vaccines
    • 6.1.2 Others (Insulin, Biopharma, Others)
  • 6.2 By Geography
    • 6.2.1 North America
      • 6.2.1.1 United States
      • 6.2.1.2 Canada
    • 6.2.2 Europe
      • 6.2.2.1 Germany
      • 6.2.2.2 United Kingdom
      • 6.2.2.3 France
      • 6.2.2.4 Italy
      • 6.2.2.5 Spain
    • 6.2.3 Asia
      • 6.2.3.1 China
      • 6.2.3.2 Japan
      • 6.2.3.3 India
      • 6.2.3.4 South Korea
      • 6.2.3.5 Australia and New Zealand
    • 6.2.4 Latin America
    • 6.2.5 Middle East and Africa

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Schott AG
    • 7.1.2 Gerresheimer AG
    • 7.1.3 Stevanato Group SPA
    • 7.1.4 NIPRO Corporation
    • 7.1.5 Kapoor Glass India Pvt. Ltd
    • 7.1.6 SGD SA (SGD Pharma)
    • 7.1.7 AAPL Solutions Pvt. Ltd
    • 7.1.8 CORNING INCORPORATED
    • 7.1.9 BOROSIL
    • 7.1.10 Stoelzle Oberglas GmbH
    • 7.1.11 Accu-Glass LLC
    • 7.1.12 Adit Containers Private Limited
    • 7.1.13 Agrado SA
    • 7.1.14 Birgimefar Group
    • 7.1.15 J. Penner Corporation
    • 7.1.16 BORMIOLI PHARMA SPA
    • 7.1.17 SISECAM

8 INVESTMENT ANALYSIS

9 FUTURE OF THE MARKET